BioSpace News Archive

Policy

Kids Up Next: FDA Panel Discussing EUA for Pfizer-BioNTech COVID-19 Vaccine

If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.

October 26, 2021
·
3 min read
·
Mark Terry
Pharm Country

Novartis Considers Sale or Spinoff of Generics Unit

Novartis is reviewing its Sandoz division to determine the best moves to maximize value for shareholders. The strategic review will explore all options for the Swiss pharma giant.

October 26, 2021
·
2 min read
·
Alex Keown
Business

Lilly, Merck and Bayer Back a New Composer for Autoimmune Therapies

Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round. The company focuses on developing treatments for celiac disease and other immune-related conditions.

October 26, 2021
·
3 min read
·
Mark Terry
Policy

Avian Flu Spike in Humans Creates Concern

Scientists are scrambling to find the cause for the sudden spike in human cases of avian influenza A (H5N6) in China to 21 this year, from only five in 2020.

October 26, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Alzheimer’s Vaccine Could Be on the Horizon

Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.

October 26, 2021
·
5 min read
·
Heather McKenzie
Drug Development

Axcella Launches Long Covid Treatment Trial in the UK

Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.

October 26, 2021
·
3 min read
·
Mark Terry
Drug Development

Moderna Says COVID-19 Vaccine Safe and Effective in Kids 6 to 11

Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.

October 26, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

Errant Escalates Complaints to Lawsuit Over bluebird bio’s Gene Therapy

The battle between bluebird bio and Errant Gene Therapeutics has escalated into a patent lawsuit. Errant alleges that bluebird’s gene therapies infringe on their patents for recombinant vectors.

October 26, 2021
·
2 min read
·
Alex Keown
Pharm Country

Investor Cash Windfall to Lengthen Lifespans, Print DNA and Fight Cancer

Cambrian Biopharma announced an oversubscribed $100 million Series C. The biotech aims to prevent age-related diseases and increase healthy lifespans.

October 26, 2021
·
4 min read
·
Kate Goodwin
Business

Jennifer Doudna’s Mammoth Links with Vertex in $700 Million Ultra-Small CRISPR Deal

Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.

October 26, 2021
·
4 min read
·
Gail Dutton